Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19

Drifa Belhadi, Nathan Peiffer-Smadja, François-Xavier Lescure, Yazdan Yazdanpanah, France Mentré, Cédric Laouénan
doi: https://doi.org/10.1101/2020.03.18.20038190
Drifa Belhadi
1Université de Paris, IAME, INSERM, F-75018 Paris, France
2Département d’Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat – Claude-Bernard, AP-HP, 75018 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: drifa.belhadi@aphp.fr
Nathan Peiffer-Smadja
1Université de Paris, IAME, INSERM, F-75018 Paris, France
3Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François-Xavier Lescure
1Université de Paris, IAME, INSERM, F-75018 Paris, France
3Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yazdan Yazdanpanah
1Université de Paris, IAME, INSERM, F-75018 Paris, France
3Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
France Mentré
1Université de Paris, IAME, INSERM, F-75018 Paris, France
2Département d’Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat – Claude-Bernard, AP-HP, 75018 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cédric Laouénan
1Université de Paris, IAME, INSERM, F-75018 Paris, France
2Département d’Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat – Claude-Bernard, AP-HP, 75018 Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Although a number of antiviral agents have been evaluated for coronaviruses there are no approved drugs available. To provide an overview of the landscape of therapeutic research for COVID-19, we conducted a review of registered clinical trials.

Methods A review of currently registered clinical trials was performed on registries, including the Chinese (chictr.org.cn) and US (clinicaltrials.gov) databases to identify relevant studies up to March, 7th 2020. The search was conducted using the search terms “2019-nCoV”, “COVID-19”, “SARS-CoV-2”, “Hcov-19”, “new coronavirus”, “novel coronavirus”. We included interventional clinical trials focusing on patients with COVID-19 and assessing antiviral drugs or agents.

Findings Out of the 353 studies identified, 115 clinical trials were selected for data extraction. Phase IV trials were the most commonly reported study type (n=27, 23%). However, 62 trials (54%) did not describe the phase of the study. Eighty percent (n=92) of the trials were randomized with parallel assignment and the median number of planned inclusions was 63 (IQR, 36-120). Open-label studies were the most frequent (46%) followed by double-blind (13%) and single blind studies (10%). The most frequently assessed therapies were: stem cells therapy (n=23 trials), lopinavir/ritonavir (n=15), chloroquine (n=11), umifenovir (n=9), hydroxychloroquine (n=7), plasma treatment (n=7), favipiravir (n=7), methylprednisolone (n=5), and remdesivir (n=5). Remdesivir was tested in 5 trials with a median of 400 (IQR, 394-453) planned inclusions per trial, while stem cells therapy was tested in 23 trials, but had a median of 40 (IQR, 23-60) planned inclusions per trial. Lopinavir/ritonavir was associated with the highest total number of planned inclusions (2606) followed by remdesivir (2155). Only 52% of the clinical trials reported the treatment dose (n=60) and only 34% (n=39) the duration. The primary outcome was clinical in 76 studies (66%), virological in 27 (23%); radiological in 9 (8%) or immunological in three studies (3%).

Interpretation Numerous clinical trials have been registered since the beginning of the COVID-19 outbreak, however, a number of information regarding drugs or trial design were lacking.

Funding None

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted March 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19
Drifa Belhadi, Nathan Peiffer-Smadja, François-Xavier Lescure, Yazdan Yazdanpanah, France Mentré, Cédric Laouénan
medRxiv 2020.03.18.20038190; doi: https://doi.org/10.1101/2020.03.18.20038190
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19
Drifa Belhadi, Nathan Peiffer-Smadja, François-Xavier Lescure, Yazdan Yazdanpanah, France Mentré, Cédric Laouénan
medRxiv 2020.03.18.20038190; doi: https://doi.org/10.1101/2020.03.18.20038190

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (173)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)